SCHEDULE: State Street Discloses 4.7% Stake in Myriad Genetics

State Street Corporation has reported beneficial ownership of 4.7% of Myriad Genetics Inc. common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Myriad Genetics Inc. common stock.
• As of March 31, 2026, State Street Corporation beneficially owns 4,424,027 shares, representing 4.7% of the class of securities.
• The filing specifies that State Street Corporation has shared voting power over 4,164,534 shares and shared dispositive power over 4,424,027 shares.
• The company's subsidiaries involved in this reporting include SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, STATE STREET GLOBAL ADVISORS TRUST COMPANY, and STATE STREET GLOBAL ADVISORS, LTD., all classified as Investment Advisers (IA).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard disclosure of institutional ownership and does not provide new operational or financial information about Myriad Genetics Inc. itself.

Positives

• State Street Corporation's investment indicates confidence in Myriad Genetics Inc. from a major financial institution.
• The filing is a routine disclosure for significant institutional ownership, suggesting stable, long-term investment rather than activist intent.

Negatives

• The filing does not contain any negative financial or operational information about Myriad Genetics Inc. itself, as it is a disclosure by an investor.
• No specific negative commentary is present within the filing from State Street Corporation regarding Myriad Genetics Inc.

Risks

• As a Schedule 13G filing, it primarily reports passive investment and does not inherently detail specific risks for Myriad Genetics Inc. The risks would be those inherent to any investment in a publicly traded company.
• Potential risks for Myriad Genetics Inc. could include market competition, regulatory changes in the healthcare and genetic testing industry, and the success of its product pipeline, though these are not detailed in this specific filing.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Myriad Genetics Inc. or State Street Corporation regarding future performance.

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by State Street Corporation, a major custodian and investment management firm, signifies a significant institutional holding in Myriad Genetics Inc. This level of ownership is common for large asset managers who hold shares on behalf of various funds and clients, reflecting a passive investment strategy rather than an attempt to influence corporate control.

Comparison to Industry Standards

• Institutional ownership stakes in the biotechnology and genetic testing sector often range from single digits to substantial percentages for large-cap companies. A 4.7% stake by a firm like State Street is within the typical range for passive institutional investment.
• Competitors in the genetic testing space, such as Illumina or Thermo Fisher Scientific, also see significant institutional ownership, with stakes often held by similar large asset managers like Vanguard, BlackRock, and State Street.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be viewed positively as it suggests a degree of stability and validation from a major financial player. However, it does not directly impact current share price or dividends.
• Employees: No direct impact is indicated by this ownership filing.
• Creditors: No direct impact is indicated by this ownership filing.
• Suppliers/Customers: No direct impact is indicated by this ownership filing.

Next Steps

• State Street Corporation will continue to hold its shares in Myriad Genetics Inc. and will file updated reports if its ownership stake changes significantly (e.g., crosses 5% or changes voting/dispositive power thresholds).
• Myriad Genetics Inc. will continue its business operations, product development, and commercialization efforts.

Key Dates

Keywords

Myriad Genetics, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Genetic Testing, Healthcare